A new American Heart Association/American College of Cardiology/multisociety dyslipidemia guideline could expand eligibility for primary prevention statin therapy to an estimated 21.5 million additional U.S. adults, according to a study published July 20 in JAMA.
The 2026 guideline, released in March, retires and replaces the 2018 AHA/ACC/multisociety cholesterol guideline, swapping the decades-old Pooled Cohort Equations for a newer risk calculator, PREVENT, which drops race as an input, adds kidney function, and is built on a much larger and more contemporary dataset. The guideline also added a 30-year ASCVD risk pathway alongside the traditional 10-year estimate and lowered the risk thresholds at which statins can be considered.
Here are four things to know from the study:
- Researchers analyzed data from 4,366 National Health and Nutrition Examination Survey participants representing 154.5 million U.S. adults ages 30 to 79 years without known atherosclerotic cardiovascular disease.
- Researchers estimated that 87.5 million U.S. adults, or 56.6% of adults ages 30 to 79 years without known atherosclerotic cardiovascular disease, would be eligible for primary prevention statin therapy under the 2026 guideline.
- Older adults account for much of the expansion. More than 93% of adults ages 70 to 79 years and 85% of adults ages 60 to 69 years would be eligible for statins, compared with 11% of adults ages 30 to 39 years.
- The newly eligible population is lower risk. Newly statin-eligible adults had a mean estimated 10-year ASCVD risk of 3.1%, compared with 6.1% among adults previously eligible for statin therapy.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.